VRNA:NSD-Verona Pharma PLC ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 45.04

Change

-0.24 (-0.53)%

Market Cap

USD 3.39B

Volume

0.26M

Analyst Target

USD 18.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.99 (+0.41%)

USD 31.66B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B

ETFs Containing VRNA

AADR AdvisorShares Dorsey Wrig.. 3.08 % 0.00 %

+0.54 (+-0.12%)

USD 0.03B
SBIO ALPS Medical Breakthrough.. 2.58 % 0.50 %

-0.04 (-0.12%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 126.56% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.56% 92% A 94% A
Trailing 12 Months  
Capital Gain 125.31% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 125.31% 92% A 94% A
Trailing 5 Years  
Capital Gain 584.50% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 584.50% 98% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 74.14% 82% B 91% A-
Dividend Return 74.14% 82% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 128.31% 33% F 18% F
Risk Adjusted Return 57.78% 96% N/A 82% B
Market Capitalization 3.39B 92% A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.